Chernett Jorey sold $4.5M of STIM

Chernett Jorey sold 3,335,411 shares of Neuronetics, Inc. (STIM) at an average of $1.34 ($1.15–$2.39, $4.48M total) across 5 trades over 2026-11-06 to 2026-11-13.

Original reporting
SEC EDGAR · Chernett Jorey
Published Nov 14, 2026, 2:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 3:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STIM
Bearish
high confidence
Mentioned
$STIM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STIMBearishMed
01

Why it matters

The disclosed sale adds immediate sell‑side pressure and may prompt short‑term price decline.

02

Market read

Primary insider sale of a mid‑cap biotech, likely to cause short‑term downward movement.

03

What to watch

Potential tax planning or diversification needs of the insider.

Relevance 6/10Novelty 8/10Timing: after-hours reaction

Background

Neuronetics (NASDAQ:STIM) develops transcranial magnetic stimulation devices for treatment‑resistant depression. Insider sales are disclosed via Form 4 filings.

Company-level read

Ticker impact

$STIMBearishHigh confidence
Context

10% owner Chernett Jorey sold 3.33M shares (~$4.5M) in open‑market transactions, reducing holdings to 7.33M shares.

Expected impact

downward pressure as the market prices in the insider sell.

Evidence & confidence

The sale represents a significant portion of the insider's stake and is disclosed via a Form 4, a primary source filing.

Market effects

May weigh on the neurotechnology/psychiatric device sector as investors watch insider sentiment.

Limited to U.S. markets where STIM trades.

Low; impact confined to the specific stock.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Chernett Jorey

    10% owner of Neuronetics who sold shares.

  • Neuronetics, Inc.

    Developer of TMS medical devices.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.